A Phase 3 interventional study of ELAPR002f Injectable Gel and Saline Control in Acne Scars, sponsored by AbbVie. Recruiting at 10 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 199 studies in Cicatrix with a site in United States — 25 open to participants now, 35 under way, 2 of them phase 3. Cicatrix · United States.
Among the 199 studies in Cicatrix with a site in United States, this one is the 2nd largest by planned enrollment of the 185 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 3, reaches primary completion later than 31 of the 34 other live ones, and was the 193rd registered.
616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.
Browse Cicatrix studies →25 of the 199 studies in Cicatrix with a site in United States are open now. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+ · Women only
University of California, Davis · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
AVAVA, Inc. · Sites in United States
Ages 18–70 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
199 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 34 · Phase 3 6 · Phase 4 5
First in 1995; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 395 is above the median of 40 across 515 interventional studies indexed under Cicatrix.
Median enrollment 25 across the 185 interventional studies, 101 across the 13 observational. Of the 131 that completed or were terminated, 56 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 199 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
AbbVie has 2 studies filed under Cicatrix — fewer than ten, so there is no comparison to draw.
9 of the studies in Cicatrix with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05478551Phase 3Henry Ford Health SystemRandomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization | 2026-12-30 |
| NCT05758181University of California, DavisUndermining Apices in Surgical Wounds | 2026-12-31 |
| NCT06448481University of California, DavisAesthetic Outcome of Intra-dermal Versus Transcutaneous Purse-string Closure | 2027-01-01 |
| NCT06171386Wake Forest University Health SciencesMicroneedling vs Dermabrasion for Early Facial Scar Resurfacing | 2027-04 |
| NCT06903208Columbia UniversityRFA for Superficial Lipomas | 2027-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 199 studies in Cicatrix with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars.
ELAPR002f injectable gel is an investigational device being developed for the treatment of facial atrophic acne scars. There are 2 cohorts in this study. In Cohort 1, all participants will receive ELAPR002f injectable gel. In Cohort 2, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to the saline active control group. Around 395 adult participants with moderate to severe atrophic acne scarring on both cheeks will be screened in the study in approximately 25 sites in the United States.
Participants will receive 3 treatments over 2 months of intradermal injections of either ELAPR002f injectable gel or saline active control and will be followed for up to an additional 12 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ELAPR002f Injectable Gel on Days 1, 31, and 61. Participants will be followed for up to 420 days.
Device: ELAPR002f Injectable Gel
Participants will receive ELAPR002f Injectable Gel on Days 1, 31, and 61. Participants will be followed for up to 420 days.
Device: ELAPR002f Injectable Gel
Participants will receive a saline control on Days 1, 31, and 61. Participants will be followed for up to 420 days.
Device: Saline Control
Intradermal Injections
Intradermal Injections
Percentage of Participants who Achieve a 20% Reduction in Acne Scar Area
The acne scar area is calculated from 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the treating investigator (TI).
Time frame: Baseline to Day 181
Number of Participants with Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Day 420
Number of Participants with Presence of Binding Antibodies
Presence of binding antibodies followed by characterization through isotyping and evaluation of cross-reactivity to endogenous tissues.
Time frame: Up to Day 420
Number of Participants with Injection Site Responses (ISRs) and Systemic Responses
Incidence of ISRs/systemic responses as recorded by e-diary. ISRs are defined as redness, pain after injection, tenderness to touch, firmness, swelling, lumps/bumps, bruising, itching and discoloration (not redness or bruising).
Time frame: Up to Day 420
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters
Vital sign parameters include body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate. The investigator will assess the results for clinical significance.
Time frame: Up to Day 420
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
Clinical laboratory parameters include tests of hematology, chemistry, and urinalysis. The investigator will assess the results for clinical significance.
Time frame: Up to Day 420
Number of Participants With Clinically Significant Changes From Baseline in Physical Measurements
Physical measurements include weight and BMI. The investigator will assess the results for clinical significance.
Time frame: Up to Day 420
Change from Baseline Procedure Pain
Participants will assess procedure pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) after each of the 3 treatment sessions.
Time frame: Up to Day 420
Number of Participants with a Positive Skin Test
Participants will undergo a skin test in the volar area of the forearm to test for hypersensitivity.
Time frame: Up to Day 420
Number of Participants with Visual Disturbance Symptoms Associated with Vascular Occlusion
Number of participants with any acute cognitive changes or any change in confrontational visual fields, ocular motility, or a worsening (1-line change or more) on the Snellen visual acuity assessment.
Time frame: Up to Day 420
Number of Participants Needing a Histology of Volar Forearm Site Biopsy
Participants who are suspected of having a hypersensitivity reaction or have a hypersensitivity reaction to the volar forearm injection site will require a punch biopsy of the volar forearm injection site.
Time frame: Up to Day 420
Change from Baseline on the Overall Score of ACNE-Q Acne Scars Questionnaire
The ACNE-Q Acne Scars questionnaire includes 10 questions that ask how much the participant is bothered by their acne scars on a 4-point scale ranging from 1=Not at all to 4=Very Much.
Time frame: Up to Day 420
Change from Baseline on the Overall Score of ACNE-Q - Appearance-Related Distress
ACNE-Q - Appearance-Related Distress questionnaire includes 8 questions that ask about how the participants describe themselves on a 4-point scale ranging from 1=Never to 4=Always.
Time frame: Up to Day 420
Change from Baseline on the Overall Score of FACE-Q Satisfaction with Skin Total Score
FACE-Q Satisfaction With Skin questionnaire includes 12 questions that ask how much the participants are satisfied or dissatisfied with their facial skin on a 4-point scale ranging from 1=Very Dissatisfied to 4=Very Satisfied.
Time frame: Up to Day 420
Percentage of Participants Achieving "Responder" Status on Either Cheek Based on the Allergan Acne Scar Improvement Scale (ASIS), as assessed by the Evaluating Investigator
A "responder" is a participant who achieves 1-grade improvement on either cheek based on the ASIS, as assessed by the EI. The ASIS is a 5-grade scale used to assess acne scar improvement ranging from 1=Almost None to 5=Severe. Each side of the face is scored separately.
Time frame: Up to Day 420
Percentage of Participants who Achieve a 20% Reduction in Acne Scar Area
The acne scar area is calculated from 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the treating investigator (TI).
Time frame: Up to Day 420
Percent Change from Baseline in Acne Scar Area
The acne scar area is measured by 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the TI.
Time frame: Up to Day 420
Percent Change from Baseline in Acne Scar Volume
The acne scar volume is measured by 3D camera imaging software. Volume is defined as the sum of the individual scar volume of the 5 most prominent scars identified by the TI.
Time frame: Up to Day 420
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Nov 2029, 49 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.